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During the 2001–2002 outbreak in Gabon, we
observed that several dogs were highly exposed to Ebola
virus by eating infected dead animals. To examine whether
these animals became infected with Ebola virus, we sam-
pled 439 dogs and screened them by Ebola virus–specific
immunoglobulin (Ig) G assay, antigen detection, and viral
polymerase chain reaction amplification. Seven (8.9%) of
79 samples from the 2 main towns, 15 (15.2%) of 99
samples from Mekambo, and 40 (25.2%) of 159 samples
from villages in the Ebola virus–epidemic area had
detectable Ebola virus–IgG, compared to only 2 (2%) of 102
samples from France. Among dogs from villages with both
infected animal carcasses and human cases, seropreva-
lence was 31.8%. A significant positive direct association
existed between seroprevalence and the distances to the
Ebola virus–epidemic area. This study suggests that dogs
can be infected by Ebola virus and that the putative infec-
tion is asymptomatic.
E
bola virus causes fulminant hemorrhagic fever in both
humans and nonhuman primates (1,2). The Zaire
Ebola virus species (Ebola virus–Z), 1 of the 4 known
species of Ebola virus, occurs in central Africa and kills
80% of infected persons within a few days (3,4). Ebola
hemorrhagic fever occurs in rare epidemics, in which the
index patient is often infected by an animal source, which
indicates that Ebola hemorrhagic fever is a zoonotic dis-
ease (5). During the past 3 years, 5 Ebola outbreaks due to
Ebola virus-Z have struck the region of central Africa,
including Gabon and Republic of Congo, and caused 334
deaths among the 428 reported human cases (5). In previ-
ous studies, we showed that each extended outbreak could
be subdivided into several independent epidemic clusters
or chains of transmission, which resulted from close con-
tact with an Ebola virus-Z–infected animal carcass.
Epidemiologic observations and genetic analyses identi-
fied gorilla, chimpanzee, and duiker carcasses as the main
sources of human cases (5). Once the species barrier has
been crossed between animals and humans, the disease
spreads among humans by direct physical contact.
Some human cases in the recent outbreak in the
Gabon/Republic of Congo region did not have a docu-
mented source of exposure to Ebola hemorrhagic fever.
Similarly, 14 (4.9%) of the 284 cases in the 1976 Sudan
outbreak (6) and 55 (17.4%) of the 316 cases during the
1995 outbreak in Kikwit (7), Democratic Republic of
Congo (DRC, former Zaire), had no direct physical contact
with an infected person or known infected carcass. These
observations point to other routes of transmission (e.g.,
human-human respiratory tract infection through droplets
and aerosols) or may suggest that other, unidentified ani-
mal sources may be involved in Ebola virus transmission
to humans.
Ebola hemorrhagic fever outbreaks occurred in villages
where people keep domestic animals, including dogs. The
dogs are not fed and have to scavenge for their food. They
eat small dead animals found near the villages and also
internal organs of wild animals hunted and slaughtered by
villagers. Some dogs are also used for hunting in the dense
forested area. Although canine infection by Ebola virus has
never been documented, domestic dogs’ behavior and diet
place them at risk.
We examined whether pet dogs could have been infect-
ed by Ebola virus and their potential role as primary or sec-
ondary sources of human infection. We conducted a
large-scale serologic survey to determine the prevalence of
Ebola virus infection in pet dogs in an Ebola virus–epi-
demic area of Gabon.
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Study Populations
We sampled 439 dogs divided into 4 groups (Table 1).
The first group comprised 102 dogs living in France (neg-
ative controls). The second group comprised 258 dogs
sampled in the area of Gabon hit by the 2001–2002 Ebola
outbreak. This group was subdivided into 2 clusters, 1 of
159 dogs from villages located between Mekambo and
Ekata and between Mekambo and Mazingo (Figure 1,
Table 1) and another of 99 dogs from Mekambo city,
where human cases were also reported. The third group
comprised 50 dogs from Libreville, the capital of Gabon,
and 29 dogs from Port Gentil, Gabon’s second largest
town, located on the Atlantic Coast (Figure 1, Table 1).
Although these 2 Gabonese towns are both located >600
km from the Ebola virus–epidemic area, several human
cases of Ebola infection, imported from the disease-epi-
demic area, were observed in Libreville during the
1996–1997 outbreak. 
Sampling
Sampling was conducted in 3 ways. 1) Dogs in
Libreville and Port Gentil were sampled in a veterinary
clinic. Blood was collected in 5-mLdry Vacutainers (VWR
International, Fontenay-sous-bois, France), and serum was
prepared by centrifugation. Serum specimens were stored
at –20°C until they were sent to the Centre International de
Recherches Médicales de Franceville (CIRMF), Gabon,
where they were stored at –80°C until testing. 2) Dogs
from the Ebola virus–endemic area were sampled in the
villages. An experienced veterinary team was located at
Mekambo, where field laboratory facilities were set up;
blood samples were collected on a daily basis in the vicin-
ity of the village by using 5-mL dry Vacutainers and
medetomidine anesthesia. The tubes were then transported
to Mekambo each evening, and serum was decanted from
whole blood. Serum samples were kept in liquid nitrogen
in 1-mL aliquots at Mekambo until they were transported
to CIRMF. Serum samples were then stored at –80°C until
serologic testing, antigen detection, and RNA amplifica-
tion were carried out. 3) Dogs in France were sampled in
the Laboratoire des Dosages Hormonaux of the Ecole
Nationale Vétérinaire de Nantes, France.
Dog owners were interviewed on their pets’ activities
(e.g., participation in hunting) and health history. The
focus of the interviews was on potential Ebola virus–
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Figure 1. Locations of the main towns of Gabon (Libreville and
Port Gentil) and the villages in the Ebola virus-epidemic area dur-
ing the 2001-2002 outbreak in Gabon. The villages where human
cases of Ebola infection were observed are indicated by "H." The
villages where both human patients and infected animal carcass
were observed are indicated by "H/A." exposure events, including human cases that occurred in
the village and among dog owners. 
Laboratory Investigations
Ebola virus–specific immunoglobulin (Ig) G was
detected by using a standard enzyme-linked immunosor-
bent assay (ELISA) method as previously described (8).
Briefly, Maxisorp plates (VWR International) were coated
with Ebola virus–Z antigens diluted 1:1,000 in phosphate-
buffered saline (PBS), overnight at 4°C. Control plates
were coated with uninfected Vero cell culture antigens in
the same conditions. Sera diluted 1:400 in 5% nonfat milk
in PBS-Tween 20 (0.1%) were added to the wells and incu-
bated overnight at 4°C. IgG binding was visualized by
using a peroxidase-labeled anti-dog IgG (Kirkegaard &
Perry Laboratories, Inc., Gaithersburg, MD, USA) and the
TMB detector system (Dynex Technologies, Issy-les-
Moulineaux, France). Optical density (OD) was measured
at 450 nm with an ELISAplate reader. For each sample we
calculated the corrected OD as the OD of the antigen-coat-
ed well minus the OD of the corresponding control well.
The cut-off value (CO) was calculated as follows: CO =
M + 3σ, where M is the average of the corrected OD of the
102 negative controls from France, and σ is the standard
deviation. Samples were considered positive when the cor-
rected OD was above the cut-off.
Samples were used for antigen detection (9) and for
viral polymerase chain reaction (PCR) amplification (10).
Three positive and 3 negative serum specimens were also
used for virus isolation (9). Briefly, Maxisorp plates were
coated with a cocktail of 7 monoclonal antibodies against
Ebola virus–Z antigens; control plates were coated with
normal mouse ascitic fluid produced from the parent
myeloma cell line. Serum was then added to the wells, fol-
lowed by hyperimmune rabbit Ebola polyvalent antiserum
and then peroxidase-conjugated goat antibodies against
rabbit IgG. The TMB Microwell peroxidase substrate sys-
tem was used to measure OD. For the detection of viral
mRNA, total RNA was isolated from serum with the
QIAmp viral RNA kit (Qiagen, Courtaboeuf, France), and
cDNA was synthesized from mRNA as previously
described. Two pairs of degenerate primers corresponding
to the L-gene of Ebola virus were used for 2 rounds of
amplification, which yielded a 298-bp fragment.
Statistical Methods
Confidence intervals for proportions were calculated by
using the Clopper and Pearson method (11). Statistical
comparisons between seroprevalence rates according to
the sampling area were performed by using the Fisher
exact test. The Cochran-Armitage test was used as a trend
test for proportions, after checking for the goodness-of-fit
of the underlying linear model (12). All tests used a 0.05
significance level. Statistical analyses were performed by
using R software (R Development Core Team; 13).
Results
A total of 439 blood samples from dogs were screened
for Ebola virus–specific IgG. Two (2%) of the 102 blood
samples from dogs living in France had detectable Ebola
virus–reactive IgG (Table 2). Seven of the 79 dogs sam-
pled in Libreville and Port Gentil (8.9% prevalence rate),
15 of the 99 dogs sampled in Mekambo (15.2% prevalence
rate), and 40 of the 159 dogs sampled in villages located
within the Ebola virus–epidemic area (25.2% prevalence
rate) had detectable IgG to Ebola virus antigens (Table 2). 
During the 2001–2002 Ebola outbreak in Gabon,
human cases of Ebola virus infection appeared only in cer-
tain villages within the Ebola virus–epidemic area (Figure
1). The prevalence of Ebola virus–reactive IgG among
dogs from the villages where humans cases occurred was
27.2%, compared to 22.4% among dogs from villages
where no human cases were noted (Table 2). In some
cases, hunters had brought back to the village an Ebola
virus–infected animal carcass found in the forest. This car-
cass was the source of human infection in the village, and
the disease then spread from human to human, both with-
in the village and to other villages by population move-
ment (Figure 1). Thus, only secondary human cases were
observed in some villages, with no identified animal
source. The prevalence rate among dogs from villages with
both an animal source and human cases was as high as
31.8%, compared to 15.4% among dogs from villages with
human cases but no identified animal source (Table 2).
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France (2.0%) than in Gabon (Table 2). In particular, it was
lower than in the 2 major towns (p = 0.043), in Mekambo
(p = 0.001), and in the Ebola virus–epidemic area (p <
0.001). The seroprevalence rate in the major towns (8.9%)
was significantly lower than that in the Ebola virus–epi-
demic area (p = 0.003). Using scores from 1 to 4 for the
canine prevalence rates in France, major towns, Mekambo
and Ebola virus–epidemic areas, we observed a significant
positive trend of linear increase (Cochran-Armitage test: p
< 0.0001) (Figure 2A).
The seroprevalence rates in dogs increased linearly as
the sampling area approached the sites of human cases, as
confirmed by the highly significant Cochran-Armitage test
for trends in proportions (p < 0.0001), which used a score
of 1 for France, 2 for major towns, 3 for Mekambo, 4 for
villages from the disease-epidemic area without human
cases, and 5 for villages from the Ebola virus–epidemic
area with human cases (Figure 2B). The result was con-
firmed when restricted to the 3 latter areas (p = 0.04).
In parallel, the seroprevalence rates in dogs increased
linearly as the sampling area approached animal sources,
as confirmed by a significant Cochran-Armitage test (p <
0.0001), using a score of 1 for France, 2 for major towns,
3 for Mekambo, 4 for villages where no animal source was
observed (with or without human cases), and 5 for villages
where an animal source was observed (with human cases)
(Figure 2C). Again, the result was confirmed when restrict-
ed to the 3 latter areas (p = 0.01).
Neither Ebola virus antigens nor nucleotide sequences
were detected in any of the positive or negative dog blood
samples. We also failed to isolate the virus from 3 positive
and 3 negative samples on VeroE6 cells.
Discussion
We investigated the potential involvement of domestic
dogs in the occurrence or dissemination of Ebola virus
hemorrhagic fever in humans. Based on a large serologic
survey of dogs in the 2001–2002 Ebola outbreak area in
Gabon, we found evidence that dogs can be infected by
Ebola virus, a finding that raises important human health
issues. The ELISA method was based on the use of Ebola
virus–Z antigens. Although cross-reactions can occur with
antibodies to other subtypes, the presence of these sub-
types in our samples is unlikely because only the Zaire
subtype circulates in the study area: all patients and nonhu-
man primates tested in this part of central Africa were
infected by the Zaire subtype alone. The 2 positive dogs in
France, an apparently Ebola virus–exempt part of the
world, could be attributed to false-positive reactions due to
the calculation of the positivity cut-off and the 1:400
serum dilution step used in the tests.
We found that 40 of 159 dogs living in the 2001–2002
Ebola virus–epidemic area had detectable Ebola
virus–specific IgG, indicating either true infection or sim-
ple antigenic stimulation. All the tests were standardized at
the 1:400 serum dilution, and most serum specimens had
high OD values even at higher dilutions, confirming the
specificity of the reactions. These data are consistent with
observations we made during the different Ebola outbreaks
that occurred in Gabon and the Republic of Congo in
recent years. We observed that some dogs ate fresh
remains of Ebola virus–infected dead animals brought
back to the villages, and that others licked vomit from
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Figure 2. Seroprevalence of Ebola virus in dogs sampled in differ-
ent areas: A) France, major towns of Gabon, Mekambo (a town
close to the disease-epidemic area) and villages in the epidemic
area; B) France, major towns of Gabon, Mekambo, villages with-
out human cases and villages with human cases; C) France, major
towns of Gabon, Mekambo, villages with and without an animal
source. Estimates are represented by squares, bounded by their
95% Clopper and Pearson confidence intervals. The dashed line
is the linear trend in proportion.Ebola virus–infected patients. Together, these findings
strongly suggest that dogs can be infected by Ebola virus,
and that some pet dogs living in affected villages were
infected during the 2001–2002 human Ebola virus out-
break. No circulating Ebola antigens or viral DNA
sequences (tested by PCR) were detected in either positive
or negative serum specimens, and attempts to isolate virus
from these samples failed. These findings indicate either
old, transient Ebola infection of the tested dogs, or anti-
genic stimulation.
Symptoms did not develop in any of these highly
exposed animals during the outbreak, a finding that tends
to support antigenic stimulation, asymptomatic, or very
mild Ebola virus infection. Wild animals, especially goril-
las and chimpanzees, can also be infected by Ebola virus,
but the infection is highly lethal and causes huge outbreaks
and massive population declines (5,14). Other animals
such as guinea pigs (15), goats (16), and horses (17)
remain asymptomatic or develop mild symptoms after
experimental infection, but Ebola virus infection has never
been observed in these species in the wild. Thus, dogs
appear to be the first animal species shown to be naturally
and asymptomatically infected by Ebola virus.
Asymptomatic Ebola infection in humans has also been
observed during outbreaks (18) but is very rare. Although
dogs can be asymptomatically infected, they may excrete
infectious viral particles in urine, feces, and saliva for a
short period before virus clearance, as observed experi-
mentally in other animals. Given the frequency of contact
between humans and domestic dogs, canine Ebola infec-
tion must be considered as a potential risk factor for human
infection and virus spread. Human infection could occur
through licking, biting, or grooming. Asymptomatically
infected dogs could be a potential source of human Ebola
outbreaks and of virus spread during human outbreaks,
which could explain some epidemiologically unrelated
human cases. Dogs might also be a source of human Ebola
outbreaks, such as the 1976 Yambuku outbreaks in
Democratic Republic of Congo (19), the 1995 Kikwit out-
break, some outbreaks that occurred in 1996 and 2004 in
Gabon and Republic of Congo (5), and the 1976 (6), 1979
(20), and 2004 (21) outbreaks in Sudan, the sources of
which are still unknown. Together, these findings strongly
suggest that dogs should be taken into consideration dur-
ing the management of human Ebola outbreaks. To con-
firm the potential human risk of Ebola virus–infected dogs,
the mechanisms of viral excretion (i.e. body fluids and
virus kinetics of excretion) should be investigated during
experimental canine infection. This research would also
offer insights into the natural resistance of dogs.
The canine seroprevalence rates in Libreville and Port
Gentil, the 2 main towns of Gabon, were significantly
higher than that observed in France, which suggests
antigenic stimulation in these towns where no endemic
cases of Ebola infection have been observed.
Epidemiologic investigations showed that most seroposi-
tive dogs in Libreville and Port Gentil had probably never
had contact with an infected source (dead animal or human
case-patient), and that they had never visited the Ebola
virus–epidemic area, in theory ruling out true infection.
They may therefore have come into contact with free viral
antigens, transmitted by aerosol or, to a lesser extent, expe-
rienced conjunctival exposure to virus-laden droplets of
urine, feces, or blood of the unknown natural host. Ebola
virus has been shown to be experimentally transmissible to
rhesus monkeys by inhalation (22) and conjunctival expo-
sure (23). Moreover, accidental transmission of Ebola
virus to 2 rhesus monkeys that had no direct contact with
experimentally infected monkeys was observed in a bio-
containment laboratory, which also suggests aerosol, con-
junctival, or oral transmission (24).
The Ebola virus reservoir species appears to extend
throughout central Africa, both in rural and urban areas
and might therefore be a small terrestrial mammal or a fly-
ing animal (bat or bird). No good candidate species has yet
been identified, despite extensive studies (25,26).
Epidemiologic observations during the 1976 outbreaks in
Democratic Republic of Congo and Sudan identified bats
as a potential reservoir (6,20), and Ebola virus nucleotide
sequences and Ebola virus–like virus capsids were detect-
ed in rodents in the Central African Republic (27). The dis-
covery of Ebola virus–positive pet dogs in undeclared
affected areas suggests that these animals live in close con-
tact with the Ebola virus reservoir, and this finding should
help to narrow the search.
One striking result of this study is the significant
increasing gradient of canine seroprevalence from France
to the Ebola virus–epidemic area, including from villages
with and without human cases in the area. The Cochran-
Armitage test for trends in proportions showed that sero-
prevalence increased linearly from France (2%), to major
towns (8.9%), then to Mekambo (15.2%), and then to vil-
lages in the Ebola virus–epidemic area (25.2%). This trend
is supported by the increasing seroprevalence as the sam-
pling area approached human cases and animal sources
(Cochran-Armitage test, p < 0.0001). These findings sug-
gest that canine seroprevalence could reflect contact with
the virus and, thus, virus activity in a given area and also
the risk for human infection.
The virus appears to jump from its natural host to
humans only in specific, but unknown, conditions.
Seroprevalence rates in dogs might serves as an indicator
of Ebola virus in regions in which no animal deaths or
human cases have been observed. 
In conclusion, this study offers the first evidence that
dogs might be asymptomatically infected by Ebola virus in
Ebola Virus Antibodies in Dogs and Human Risk
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 3, March 2005 389the wild. This finding has potential implications for
preventing and controlling human outbreaks. The increas-
ing canine seroprevalence gradient from low-risk to at-risk
Ebola virus–endemic areas indicates that this seropreva-
lence might be used as an epidemiologic indicator of virus
circulation in regions where no other means of virus detec-
tion are available.
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